Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.
Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, Kouchakji E, Rocha F, Carrier E. Picozzi V, et al. Among authors: porter s. ESMO Open. 2020 Aug;5(4):e000668. doi: 10.1136/esmoopen-2019-000668. ESMO Open. 2020. PMID: 32817130 Free PMC article. Clinical Trial.
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G. Richeldi L, et al. Among authors: porter s. Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28. Lancet Respir Med. 2020. PMID: 31575509 Clinical Trial.
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity.
Clukers J, Lanclus M, Mignot B, Van Holsbeke C, Roseman J, Porter S, Gorina E, Kouchakji E, Lipson KE, De Backer W, De Backer J. Clukers J, et al. Among authors: porter s. Respir Res. 2018 Nov 6;19(1):213. doi: 10.1186/s12931-018-0918-5. Respir Res. 2018. PMID: 30400950 Free PMC article. Clinical Trial.
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.
Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, Brown KK, Flaherty KR, Wencel M, Wanger J, Neff T, Valone F, Stauffer J, Porter S. Raghu G, et al. Among authors: porter s. Eur Respir J. 2016 May;47(5):1481-91. doi: 10.1183/13993003.01030-2015. Epub 2016 Mar 10. Eur Respir J. 2016. PMID: 26965296 Free article. Clinical Trial.
The evolutionary genomics of adaptation to stress in wild rhizobium bacteria.
Kehlet-Delgado H, Montoya AP, Jensen KT, Wendlandt CE, Dexheimer C, Roberts M, Torres Martínez L, Friesen ML, Griffitts JS, Porter SS. Kehlet-Delgado H, et al. Among authors: porter ss. Proc Natl Acad Sci U S A. 2024 Mar 26;121(13):e2311127121. doi: 10.1073/pnas.2311127121. Epub 2024 Mar 20. Proc Natl Acad Sci U S A. 2024. PMID: 38507447
1,684 results